Immune and molecular correlates in melanoma treated with immune checkpoint blockade
暂无分享,去创建一个
[1] Rosie Qin,et al. Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. , 2016, International journal of radiation oncology, biology, physics.
[2] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[3] Nicola D. Roberts,et al. Germline MC1R status influences somatic mutation burden in melanoma , 2016, Nature Communications.
[4] A. Ray,et al. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma , 2016, Oncotarget.
[5] J. Wolchok,et al. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment , 2016, Experimental dermatology.
[6] H. Pehamberger,et al. Human Determinants and the Role of Melanocortin-1 Receptor Variants in Melanoma Risk Independent of UV Radiation Exposure. , 2016, JAMA dermatology.
[7] M. Postow,et al. Irradiation and immunotherapy: From concept to the clinic , 2016, Cancer.
[8] S. Aiba,et al. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in‐transit melanoma: Two cases reports , 2016, The Journal of dermatology.
[9] L. French,et al. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy , 2016, Clinical Cancer Research.
[10] Yu Shyr,et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.
[11] N. Meyer,et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. , 2015, Melanoma research.
[12] R. Dummer,et al. The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.
[13] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[14] G. Gibney,et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.
[15] M. Donia,et al. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. , 2015, Cancer research.
[16] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[17] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Matteo Brunelli,et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.
[19] P. Fernández-Peñas,et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. , 2015, Melanoma research.
[20] P. Hwu,et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma , 2015, Cancer Immunology Research.
[21] A. Zwinderman,et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[23] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[24] D. Fisher,et al. The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. , 2014, Archives of biochemistry and biophysics.
[25] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[26] David E. Fisher,et al. The melanoma revolution: From UV carcinogenesis to a new era in therapeutics , 2014, Science.
[27] Lingzhi Ge,et al. Induction of vitiligo after imiquimod treatment of condylomata acuminata , 2014, BMC Infectious Diseases.
[28] M. Postow,et al. Checkpoint blocking antibodies in cancer immunotherapy , 2014, FEBS letters.
[29] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] N. Popitsch,et al. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.
[31] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[32] D. Kouba,et al. Imiquimod-induced depigmentation: report of two cases and review of the literature. , 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[33] Jochen K. Lennerz,et al. A UV-independent pathway to melanoma carcinogenesis in the redhair-fairskin background , 2012, Nature.
[34] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[35] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[36] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[37] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[38] K. Brown,et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.
[39] A. Kawada,et al. Nonsegmental Vitiligo and Autoimmune Mechanism , 2011, Dermatology research and practice.
[40] J. Drijfhout,et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. , 2011, The Journal of investigative dermatology.
[41] J. Allison,et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.
[42] Tom Royce,et al. A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.
[43] F. Garrido,et al. HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank , 2009, Cancer Immunology, Immunotherapy.
[44] T. Schumacher,et al. T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model , 2008, Journal of immunotherapy.
[45] S. O’Day,et al. Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) , 2007, Cancer.
[46] S. Rosenberg,et al. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis , 2007, Journal of immunotherapy.
[47] David E. Fisher,et al. Central Role of p53 in the Suntan Response and Pathologic Hyperpigmentation , 2007, Cell.
[48] F. Garrido,et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines , 2007, BMC Cancer.
[49] S. O’Day,et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. , 2006, The Journal of investigative dermatology.
[50] S. Rosenberg,et al. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. , 2006, Blood.
[51] D. Fisher,et al. MITF: master regulator of melanocyte development and melanoma oncogene. , 2006, Trends in molecular medicine.
[52] J. Kirkwood,et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.
[53] T. Golub,et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.
[54] S. Rosenberg,et al. Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression , 2004, Journal of immunotherapy.
[55] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[56] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[57] Sridhar Ramaswamy,et al. Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.
[58] J. Ting,et al. Constitutive Expression of MHC Class II Genes in Melanoma Cell Lines Results from the Transcription of Class II Transactivator Abnormally Initiated from Its B Cell-Specific Promoter1 , 2001, The Journal of Immunology.
[59] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] O. Mandelboim,et al. Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[61] F. Marincola,et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.
[62] J. Bystryn,et al. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. , 1995, Archives of dermatology.
[63] S. Rosenberg,et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.
[64] J. Cairncross,et al. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets , 1982, The Journal of experimental medicine.
[65] M. Silverstein,et al. BCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience , 1974, Annals of surgery.
[66] W. C. Sumner. Spontaneous regression of melanoma. Report of a case , 1953 .
[67] J. Soria,et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.
[68] M. Mandalà,et al. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. , 2014, Critical reviews in oncology/hematology.
[69] Jochen K. Lennerz,et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair / fair skin background , 2012 .
[70] S. Rosenberg,et al. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[71] V. McGovern. SPONTANEOUS REGRESSION OF MELANOMA , 1975, Pathology.